Dear ,

In the current issue of the OncoWuXi Newsletter, we share with you the update on our service and newly established capabilities.
 
OncoWuXi Newsletter will continue to keep you up to date with our recent progress in cancer research. As a part of the WuXi Biology, our top-notch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases, and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.
Translational Oncology
BTKI-resistant Tumor Models

(1)  Ibrutinib-induced resistant models
  • Ibrutinib-resistant diffuse large B-cell lymphoma LY-24-0041 model
  • Ibrutinib-resistant mantle cell lymphoma Mino model

(2)  Genetically engineered mantle cell lymphoma REC-1 cell line carrying BTK C481S


Fulvestrant & Tamoxifen-induced Resistant MCF-7 Model
Radiation Platform for Preclinical Research
Immuno-Oncology
ADC-related Platform for Preclinical Research

(1)  ADC-related in vitro assays
  • Target validation and antibody binding assay
  • Antibody internalization assay
  • Cell viability assay
  • Bystander killing assay
  • ADCC and ADCP assay

(2)  WuXi AppTec ADC-related in vivo models
  • CDX and PDX models covering multiple targets (HER2, CLDN18.2, CD30, CD33, BCMA, Trop-2, CD79b, Nectin-4, etc.)
We sincerely appreciate your interest, time and support, and would like to hear your feedback so that we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns. 
 
Best regards,
WuXi AppTec OncoWuXi Team